

Jiang-Ke Qin,<sup>a</sup> Cheng-Zhu Liao,<sup>b</sup>  
Yong-Tao Wang,<sup>a</sup> Xian-Zhang  
Bu,<sup>c</sup> Zhi-Shu Huang<sup>c</sup> and  
Lian-Quan Gu<sup>a,c\*</sup>

<sup>a</sup>School of Chemistry and Chemical Engineering, Sun Yat-Sen (Zhongshan) University, Guangzhou 510275, People's Republic of China, <sup>b</sup>Instrumentation Analysis and Research Center, Sun Yat-Sen (Zhongshan) University, Guangzhou 510275, People's Republic of China, and <sup>c</sup>School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510080, People's Republic of China

Correspondence e-mail: lcz613@163.com

#### Key indicators

Single-crystal X-ray study  
T = 293 K  
Mean  $\sigma(\text{C}-\text{C}) = 0.002 \text{ \AA}$   
R factor = 0.040  
wR factor = 0.126  
Data-to-parameter ratio = 15.2

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.


## 8,9-Dihydro-1,6-dimethylphenanthro[1,2-*b*]-furan-10,11-dione

The title compound,  $\text{C}_{18}\text{H}_{14}\text{O}_3$ , also known as 1,2-dihydro-tanshinquinone, contains a four-ring system. No classical hydrogen bonds are found in the structure.

Received 25 January 2005  
Accepted 21 February 2005  
Online 4 March 2005

#### Comment

1,2-Dihydro-tanshinquinone is one of the tanshinones isolated from the root of the Chinese traditional herb, *Salvia miltiorrhiza*, which has broad pharmacological activities, such as antibacterial (Fang *et al.*, 1976), antitumour (Ryu *et al.*, 1997) and antiplatelet aggregation (Onitsuka *et al.*, 1983). Tanshinones have been used to treat coronary diseases (Chang *et al.*, 1991), cerebrovascular and neurasthenic insomnia problems (Yagi *et al.*, 1989). The structure of 1,2-dihydro-tanshinquinone (or 8,9-dihydro-1,6-dimethylphenanthro[1,2-*b*]furan-10,11-dione), (I), was previously elucidated on the basis of spectroscopic analysis (Feng & Li, 1980). We report here its crystal structure.



The X-ray study of (I) confirms the previously proposed structure based on the spectroscopic data. The asymmetric unit of (I) consists of one independent molecule (Fig. 1). No classical hydrogen bonds are found. The molecular skeleton consists of a four-ring system in which the furan ring is essentially coplanar with the fused six-membered ring, with a torsion angle  $\text{C}15-\text{C}13-\text{C}14-\text{O}1 = -0.75 (15)^\circ$  (Table 1), while the terminal six-membered ring is in a twist-boat form, with torsion angles  $\text{C}10-\text{C}1-\text{C}2-\text{C}3 = -46.82 (16)^\circ$  and  $\text{C}3-\text{C}4-\text{C}5-\text{C}10 = -17.63 (19)^\circ$  (Table 1).

#### Experimental

Compound (I) was isolated from the root of *Salvia miltiorrhiza*. The root was extracted with EtOH and concentrated *in vacuo*. The residue was subjected to silica-gel column chromatography, eluting with EtOAc–petroleum ether (5:95 *v/v*), yielding the title compound, (I). Crystals of (I) were obtained by slow evaporation of an EtOAc–petroleum ether solution. The compound identity was confirmed by NMR and FAB–MS spectroscopy.  $^1\text{H}$  NMR (500 MHz;  $\text{CDCl}_3$ ): 7.55 (*d*, 1H,  $J = 8$  Hz, H6), 7.42 (*d*, 1H,  $J = 8$  Hz, H7), 7.22 (*s, br*, 1H, H16), 6.05 (*t, br*, 1H,  $J = 4$  Hz, H3), 3.33 (*t*, 2H,  $J = 8$  Hz,

H1), 2.29 (*m*, 2H, H2), 2.27 (*s*, *br*, 3H, H17), 2.06 (*d*, 3H, *J* = 1 Hz, H18). FAB-MS *m/z*: 279 (*M* + 1).

#### Crystal data

C<sub>18</sub>H<sub>14</sub>O<sub>3</sub>  
*M<sub>r</sub>* = 278.29  
 Triclinic, *P* $\bar{1}$   
*a* = 7.9225 (11) Å  
*b* = 8.0119 (10) Å  
*c* = 11.7565 (14) Å  
 $\alpha$  = 83.979 (2)°  
 $\beta$  = 86.251 (2)°  
 $\gamma$  = 64.422 (2)°  
*V* = 669.22 (15) Å<sup>3</sup>

*Z* = 2  
*D<sub>x</sub>* = 1.382 Mg m<sup>-3</sup>  
 Mo *K*α radiation  
 Cell parameters from 999 reflections  
 $\theta$  = 2.8–26.0°  
 $\mu$  = 0.09 mm<sup>-1</sup>  
*T* = 293 (2) K  
 Block, red  
 0.50 × 0.41 × 0.21 mm

#### Data collection


Bruker SMART CCD area-detector diffractometer  
 $\varphi$  and  $\omega$  scans  
 Absorption correction: multi-scan (*SADABS*; Sheldrick, 1996)  
*T<sub>min</sub>* = 0.955, *T<sub>max</sub>* = 0.980  
 7564 measured reflections

2897 independent reflections  
 2409 reflections with *I* > 2σ(*I*)  
*R<sub>int</sub>* = 0.013  
 $\theta_{\max}$  = 27.1°  
*h* = -10 → 10  
*k* = -10 → 10  
*l* = -15 → 15

#### Refinement

Refinement on *F*<sup>2</sup>  
*R* [*F*<sup>2</sup> > 2σ(*F*<sup>2</sup>)] = 0.040  
*wR* (*F*<sup>2</sup>) = 0.127  
*S* = 1.04  
 2897 reflections  
 190 parameters  
 H-atom parameters constrained

$w = 1/[\sigma^2(F_o^2) + (0.0731P)^2 + 0.1042P]$   
 where  $P = (F_o^2 + 2F_c^2)/3$   
 $(\Delta/\sigma)_{\max} < 0.001$   
 $\Delta\rho_{\max} = 0.26 \text{ e \AA}^{-3}$   
 $\Delta\rho_{\min} = -0.16 \text{ e \AA}^{-3}$



**Figure 1**

Molecular structure of the asymmetric unit of the title compound, showing 30% probability displacement ellipsoids. H atoms are drawn as small spheres of arbitrary radii.

H atoms were positioned geometrically and were refined as riding on the parent C atoms, with C–H distances of 0.93–0.97 Å [*U<sub>iso</sub>*(H) = 1.2*U<sub>eq</sub>*(C)].

Data collection: *SMART* (Bruker, 1998); cell refinement: *SMART*; data reduction: *SAINT-Plus* (Bruker, 1999); program(s) used to solve structure: *SHELXS97* (Sheldrick, 1997); program(s) used to refine structure: *SHELXL97* (Sheldrick, 1997); molecular graphics: *SHELXTL* (Bruker, 1998); software used to prepare material for publication: *SHELXTL*.

**Table 1**

Selected geometric parameters (Å, °).

O1–C14	1.3545 (14)	C13–C14	1.3617 (17)
O1–C16	1.3779 (17)	C13–C15	1.4365 (19)
C8–C7	1.3875 (16)	C13–C12	1.4434 (17)
C8–C9	1.4198 (15)	C11–C12	1.5628 (19)
C8–C14	1.4394 (18)	O2–C12	1.2126 (15)
C9–C10	1.4032 (17)	C6–C7	1.3722 (18)
C9–C11	1.4949 (16)	C1–C2	1.5174 (19)
O3–C11	1.2092 (15)	C4–C3	1.3375 (19)
C10–C5	1.4220 (16)	C4–C18	1.4982 (19)
C10–C1	1.5111 (16)	C2–C3	1.4865 (19)
C5–C6	1.3960 (16)	C16–C15	1.343 (2)
C5–C4	1.4749 (18)	C15–C17	1.495 (2)
C14–O1–C16	105.68 (10)	O2–C12–C11	118.76 (11)
O3–C11–C9	123.76 (12)	C3–C4–C5	119.47 (12)
O1–C14–C13	110.26 (11)	C3–C2–C1	111.73 (11)
O1–C14–C8	121.36 (10)	C4–C3–C2	121.47 (13)
C10–C1–C2	112.52 (10)	C15–C16–O1	112.25 (12)
O2–C12–C13	125.18 (13)		
C10–C5–C4–C3	–17.63 (19)	C5–C4–C3–C2	–2.3 (2)
C10–C1–C2–C3	–46.82 (16)		

This research was supported by grants from the National Natural Science Foundation of China (No. 20272085) and from the Guangzhou High Technology Development Project (No. 200221-E5011).

#### References

- Bruker (1998). *SMART* (Version 5.0) and *SHELXTL* (Version 5.1). Bruker AXS Inc., Madison, Wisconsin, USA.  
 Bruker (1999). *SAINT-Plus*. Version 6. Bruker AXS Inc., Madison, Wisconsin, USA.  
 Chang, H.-M., Chui, K.-Y., Tan, F. W. L., Yang, Y., Zhong, Z.-P., Lee, C.-M., Sham, H.-L. & Wong, H. N. C. (1991). *J. Med. Chem.* **34**, 1675–1692.  
 Fang, C.-N., Chang, P.-L. & Hsu, T.-P. (1976). *Acta Chim. Sin.* **34**, 197–209.  
 Feng, B.-S. & Li, S.-R. (1980). *Acta Pharm. Sin.* **15**, 489–493.  
 Onitsuka, M., Fujii, M., Shinma, N. & Maruyama, H. B. (1983). *Chem. Pharm. Bull.* **31**, 1670–1675.  
 Ryu, S. Y., Lee, C. O. & Choi, S. U. (1997). *Planta Med.* **63**, 339–342.  
 Sheldrick, G. M. (1996). *SADABS*. University of Göttingen, Germany.  
 Sheldrick, G. M. (1997). *SHELXS97* and *SHELXL97*. University of Göttingen, Germany.  
 Yagi, A., Fujimoto, K., Tanonaka, K., Hirai, K. & Takeo, S. (1989). *Planta Med.* **55**, 51–54.